94 related articles for article (PubMed ID: 25017035)
1. Molecular dynamics study-guided identification of cyclic amine structures as novel hydrophobic tail components of hPPARγ agonists.
Tanaka Y; Gamo K; Oyama T; Ohashi M; Waki M; Matsuno K; Matsuura N; Tokiwa H; Miyachi H
Bioorg Med Chem Lett; 2014 Aug; 24(16):4001-5. PubMed ID: 25017035
[TBL] [Abstract][Full Text] [Related]
2. Different structures of the two peroxisome proliferator-activated receptor gamma (PPARγ) ligand-binding domains in homodimeric complex with partial agonist, but not full agonist.
Ohashi M; Oyama T; Miyachi H
Bioorg Med Chem Lett; 2015 Jul; 25(13):2639-44. PubMed ID: 25987371
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of a series of α-benzyl phenylpropanoic acid-type peroxisome proliferator-activated receptor (PPAR) gamma partial agonists with improved aqueous solubility.
Ohashi M; Oyama T; Putranto EW; Waku T; Nobusada H; Kataoka K; Matsuno K; Yashiro M; Morikawa K; Huh NH; Miyachi H
Bioorg Med Chem; 2013 Apr; 21(8):2319-2332. PubMed ID: 23490155
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor gamma (PPARγ) has multiple binding points that accommodate ligands in various conformations: Structurally similar PPARγ partial agonists bind to PPARγ LBD in different conformations.
Ohashi M; Gamo K; Oyama T; Miyachi H
Bioorg Med Chem Lett; 2015 Jul; 25(14):2758-62. PubMed ID: 26025876
[TBL] [Abstract][Full Text] [Related]
5. Structural Biology Inspired Development of a Series of Human Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Ligands: From Agonist to Antagonist.
Miyachi H
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835351
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptors (PPARs) have multiple binding points that accommodate ligands in various conformations: phenylpropanoic acid-type PPAR ligands bind to PPAR in different conformations, depending on the subtype.
Kuwabara N; Oyama T; Tomioka D; Ohashi M; Yanagisawa J; Shimizu T; Miyachi H
J Med Chem; 2012 Jan; 55(2):893-902. PubMed ID: 22185225
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
Montanari R; Saccoccia F; Scotti E; Crestani M; Godio C; Gilardi F; Loiodice F; Fracchiolla G; Laghezza A; Tortorella P; Lavecchia A; Novellino E; Mazza F; Aschi M; Pochetti G
J Med Chem; 2008 Dec; 51(24):7768-76. PubMed ID: 19053776
[TBL] [Abstract][Full Text] [Related]
8. Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies.
Mahindroo N; Wang CC; Liao CC; Huang CF; Lu IL; Lien TW; Peng YH; Huang WJ; Lin YT; Hsu MC; Lin CH; Tsai CH; Hsu JT; Chen X; Lyu PC; Chao YS; Wu SY; Hsieh HP
J Med Chem; 2006 Feb; 49(3):1212-6. PubMed ID: 16451087
[TBL] [Abstract][Full Text] [Related]
9. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
Waku T; Shiraki T; Oyama T; Fujimoto Y; Maebara K; Kamiya N; Jingami H; Morikawa K
J Mol Biol; 2009 Jan; 385(1):188-99. PubMed ID: 18977231
[TBL] [Abstract][Full Text] [Related]
10. [Design, synthesis, and PPARalpha/gamma agonistic activity of novel tetrahydroisoquinoline derivatives].
Yu R; Zhou YL; Huan Y; Liu Q; Shen ZF; Liu ZZ
Yao Xue Xue Bao; 2011 Mar; 46(3):311-6. PubMed ID: 21626786
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and in vitro evaluation of a series of α-substituted phenylpropanoic acid PPARγ agonists to further investigate the stereochemistry-activity relationship.
Ohashi M; Nakagome I; Kasuga J; Nobusada H; Matsuno K; Makishima M; Hirono S; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2012 Nov; 20(21):6375-83. PubMed ID: 23022278
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic flavonoids as agonists of peroxisome proliferator-activated receptor gamma on human cervical and prostate cancer cells.
Lee JY; Kim JK; Cho MC; Shin S; Yoon DY; Heo YS; Kim Y
J Nat Prod; 2010 Jul; 73(7):1261-5. PubMed ID: 20583750
[TBL] [Abstract][Full Text] [Related]
13. Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.
Rudolph J; Chen L; Majumdar D; Bullock WH; Burns M; Claus T; Dela Cruz FE; Daly M; Ehrgott FJ; Johnson JS; Livingston JN; Schoenleber RW; Shapiro J; Yang L; Tsutsumi M; Ma X
J Med Chem; 2007 Mar; 50(5):984-1000. PubMed ID: 17274610
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and structural analysis of phenylpropanoic acid-type PPARγ-selective agonists: discovery of reversed stereochemistry-activity relationship.
Ohashi M; Oyama T; Nakagome I; Satoh M; Nishio Y; Nobusada H; Hirono S; Morikawa K; Hashimoto Y; Miyachi H
J Med Chem; 2011 Jan; 54(1):331-41. PubMed ID: 21128600
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for the improved potency of peroxisome proliferator-activated receptor (PPAR) agonists.
Peng YH; Coumar MS; Leou JS; Wu JS; Shiao HY; Lin CH; Lin WH; Lien TW; Chen X; Hsu JT; Chao YS; Huang CF; Lyu PC; Hsieh HP; Wu SY
ChemMedChem; 2010 Oct; 5(10):1707-16. PubMed ID: 20734309
[TBL] [Abstract][Full Text] [Related]
16. Mode of peroxisome proliferator-activated receptor γ activation by luteolin.
Puhl AC; Bernardes A; Silveira RL; Yuan J; Campos JL; Saidemberg DM; Palma MS; Cvoro A; Ayers SD; Webb P; Reinach PS; Skaf MS; Polikarpov I
Mol Pharmacol; 2012 Jun; 81(6):788-99. PubMed ID: 22391103
[TBL] [Abstract][Full Text] [Related]
17. Structure-dependent binding and activation of perfluorinated compounds on human peroxisome proliferator-activated receptor γ.
Zhang L; Ren XM; Wan B; Guo LH
Toxicol Appl Pharmacol; 2014 Sep; 279(3):275-283. PubMed ID: 24998974
[TBL] [Abstract][Full Text] [Related]
18. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
Keil S; Matter H; Schönafinger K; Glien M; Mathieu M; Marquette JP; Michot N; Haag-Diergarten S; Urmann M; Wendler W
ChemMedChem; 2011 Apr; 6(4):633-53. PubMed ID: 21400663
[TBL] [Abstract][Full Text] [Related]
19. Multi-conformation dynamic pharmacophore modeling of the peroxisome proliferator-activated receptor γ for the discovery of novel agonists.
Sohn YS; Park C; Lee Y; Kim S; Thangapandian S; Kim Y; Kim HH; Suh JK; Lee KW
J Mol Graph Model; 2013 Nov; 46():1-9. PubMed ID: 24104184
[TBL] [Abstract][Full Text] [Related]
20. SAR-oriented discovery of peroxisome proliferator-activated receptor pan agonist with a 4-adamantylphenyl group as a hydrophobic tail.
Kasuga J; Yamasaki D; Ogura K; Shimizu M; Sato M; Makishima M; Doi T; Hashimoto Y; Miyachi H
Bioorg Med Chem Lett; 2008 Feb; 18(3):1110-5. PubMed ID: 18162399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
